Marco Meglio

Similar to results at 24-months, findings showed improvements in patient outcomes with the SCS System including quality of life, functional ability, mood, and sleep.

The trial’s 2-stage design seeks to answer questions about the dosing and efficacy of brivaracetam, a previously approved agent for partial-onset seizures in patients with childhood absence epilepsy and juvenile absence epilepsy.

After a 12-month period, patients were able to use the implant for routine digital activities, such as texting, emailing, personal finance, online shopping, and communication of care needs.

Nearly 94% of nusinersen doses recorded in electronic health records database and more than 80% of doses recorded in the claims databases were received on time according to the recommended dosing schedule.

In the letter, the FDA specifically required that Eli Lilly provide data from at least 100 patients who received a minimum of 12 months of continuous treatment with donanemab.

The study provided class II evidence that CYP2C19 loss of function carriers with minor stroke or transient ischemic attack at low risk, but not high risk, of recurrent stroke received greater benefit from ticagrelor and aspirin rather than clopidogrel and aspirin.

Between sexes, females with cluster headache reported longer bouts than male participants and used prophylactic treatment more often, as well as higher rates of diurnal rhythmicity.

The executive director of Cure CMD provided perspective on a new 10-month program that aims to align patient and clinician perspectives on certain rare neuromuscular disorders.

Featuring a cohort of more than 500 patients with NMOSD, data showed that those with comorbidities exhibit multiple presentations and are more likely to relapse after immunotherapy.

PIRA was associated with, for most patients, a sustained accumulation of disability, which was strongly associated with unfavorable long-term outcomes.

Despite previous data suggesting no link, the CDC and FDA will continue to review all evidence for possible increased risk of ischemic stroke.

Plain sulfonamide diuretics was identified as a drug chemical subgroup potentially inversely associated with Parkinson disease risk, while weaker signals included insulin and ß2-adrenergic agonists.

Patients who had higher baseline REM without atonia levels were associated with the largest treatment effects on RSWA with a single 50 mg dose of ulotaront.

Susan Abushakra, MD, chief medical officer at Alzheon, provided insight on findings from a phase 2 study in which ALZ-801 showed beneficial effects on cognition, Aß 42/40, and brain atrophy.

Not previously explored, new findings showed links between antiseizure drug prescriptions and incident PD, with trends towards increased risk in those with greater number of prescription issues and multiple AEDs.

In preclinical animal models, NRL-1049 showed an ability to decrease ROCK-2 activation, a pathway that is hyperactivated in patients with cerebral cavernous malformations.

The trial found no evidence of any clinically relevant benefit from the CHESS intervention across multiple outcomes at multiple time points, nor in any sensitivity or subgroup analyses.

DaxibotulinumtoxinA, the first and only peptide formulated neuromodulator, has been shown to be safe and well tolerated in doses of 125 and 250 units, with clinically meaningful effect observed by both patients and clinicians.

The virtual care program built by The Ohio State University Wexner Medical Center allows for expanded access to patient care in rural areas, improved decision-making, and hands-on experience for young neurologists.

The president and chief executive officer of INmune bio provided perspective on the need to diversify the Alzheimer treatment landscape and the potential role of TNF inhibitors like XPro1595.

In addition to improving ON time in patients with Parkinson disease, ND0612 was well tolerated, with only 6.3% of patients randomized to the treatment discontinuing the trial.

Approved under the accelerated approval pathway, the current indication for lecanemab states the company must provide phase 4 study evidence to confirm the agent’s effect in Alzheimer disease.

For the first time ever, investigators identified a treatment benefit that extends the time to clinical conversion in RIS and reduces new or newly-enlarging T-weighted hyperintense lesions.

Marketed as Leqembi, the agent was approved through the accelerated approval pathway and was based on a major study featuring almost 900 patients with early Alzheimer disease.

Findings from a large-scale trial of adults aged 65 and older with Parkinson disease showed that treatment with pimavanserin was associated with lower risk of mortality than other atypical antipsychotics.

In the phase 3 Clarity AD trial, a 65-year-old patient treated with lecanemab died because of multiple cerebral hemorrhages after undergoing tissue plasminogen activator therapy for ischemic stroke.

The increased risk of dementia in patients showing early orthostatic hypotension was independent of the presence of concomitant supine hypertension and other factors associated with cognitive impairment.

With this new approval, the Zoom RDL becomes the newest addition to Imperative’s Zoom Stroke Solution, a complete stroke system designed for effective clot removal in ischemic stroke.

Data from a cohort of nearly 100 patients with Parkinson disease suggest there are shared nondopaminergic pathogenic mechanisms between depression and postural instability symptoms of the disease.

The director of the Montefiore Einstein Center for the Aging Brain provided perspective on a new study assessing the use of a novel tool aimed to confirm patients’ cognitive complaints and issues with mobility.